Eton and Azurity’s Eprontia (topiramate) Receives the US FDA’s Approval for the Treatment of Seizures and Migraines
Shots:
- The US FDA has approved Eprontia (25mg/mL) oral solution as a monothx for partial-onset or primary generalized tonic-clonic seizures. The oral solution is also approved as an adjunctive treatment for the same indication or seizures associated with Lennox-Gastaut syndrome in patients aged ≥2yrs. along with treatment of migraine in patients aged ≥12 yrs.
- Azurity will lead the commercialization of the product & is expected to be available at the end of 2021
- Eprontia is the 1st oral liquid formulation of topiramate to be approved by the US FDA. Eton will receive a $5M milestone upon the commercial launch of Eprontia & is eligible to receive commercial milestones along with royalties
Ref: Globe Newswire | Image: Eton
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com